SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?


To: Laurens who wrote (77)2/25/1998 3:17:00 PM
From: Xavier  Respond to of 1834
 
Laurens: It would seem that this company is on solid footing, but the stock price is extremely unstable! I am a long with this one and have been nothing but disappointed! In my discussions with Mr. Lyons, he all but guaranteed that we would see some strengthening of this stock price but it just doesn't seem to be happening. I think that it is dead money until they can announce something that will prove future income. As of now, it is all a wild guess!

This is depressing. Maybe they can send me a drug that will allow me to forget everthing until they have something that will make people stand up and take notice.



To: Laurens who wrote (77)3/3/1998 2:47:00 PM
From: Tuan Phan  Read Replies (1) | Respond to of 1834
 
Laurens,

I reviewed NBIX and and like it very much. The market is large, management is great, and the primary product is not to far away from potential NDA filing (two to three years).

My report can be found at:

hybridinvestor.com

Tuan

p.s. I am usually hesitant investing in Biotech companies.